Compare ARMP & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | DPRO |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Canada |
| Employees | N/A | 69 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 73.2M |
| IPO Year | 1996 | 2019 |
| Metric | ARMP | DPRO |
|---|---|---|
| Price | $3.02 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.50 | $9.60 |
| AVG Volume (30 Days) | 75.7K | ★ 759.3K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $83.72 |
| Revenue Next Year | N/A | $138.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.40 | $1.99 |
| 52 Week High | $14.98 | $10.62 |
| Indicator | ARMP | DPRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 21.01 |
| Support Level | $2.77 | N/A |
| Resistance Level | $3.96 | $5.77 |
| Average True Range (ATR) | 0.44 | 0.27 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 43.35 | 2.76 |
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.